Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use WIXELA INHUB® safely and effectively. See full prescribing information for WIXELA INHUB® . WIXELA INHUB® (fluticasone propionate and salmeterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2000
Medication labelWhy this: Advisory · dailymed-prescription
Wixela Inhub® is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. Wixela Inhub® should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA). Wixela Inhub® is NOT indicated for the relief of acute bronchospasm. Wixela Inhub® 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Wixela Inhub® 250/50 is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. Wixela Inhub® 250/50 twice daily is the only approved dosage for the treatment of COPD because an efficacy advantage of the higher strength Wixela Inhub® 500/50 over Wixela Inhub® 250/50 has not been demonstrated. Wixela Inhub® is NOT indicated for the relief of acute bronchospasm.
- generic_name
- fluticasone propionate and salmeterol
- product_names
- fluticasone propionate and salmeterol
- ndc
- 63629-4989, 0378-9321, 63629-4989-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en